OncoMatch/Clinical Trials/NCT05190471
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Is NCT05190471 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide and Decitabine (in combination with BP1002) for acute myeloid leukemia, in relapse.
Treatment: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide · Decitabine (in combination with BP1002) — This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: PML PML-RARA fusion
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any therapy known to be active for refractory/relapsed AML — refractory/relapsed
failed treatment with available therapies known to be active for refractory/relapsed AML
Cannot have received: anti-cancer therapy
Exception: hydroxyurea or leukapheresis
Receipt of any anti-cancer therapy within 14 days prior to C1D1, with the exception of hydroxyurea or leukapheresis
Cannot have received: investigational agent
Participants may not be receiving any other investigational agents
Lab requirements
Kidney function
Estimated creatinine clearance ≥60 mL/min (Cockcroft-Gault equation)
Liver function
AST and ALT ≤2.5x ULN; total bilirubin ≤1.5x ULN (waiver possible with justification)
AST and ALT ≤2.5x ULN; total bilirubin ≤1.5x ULN (waiver possible); estimated creatinine clearance ≥60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Scripps Green Hospital · La Jolla, California
- UCLA Medical Center · Los Angeles, California
- Weill Cornell Medical College - NewYork-Presbyterian Hospital · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify